ABSTRACT
INTRODUCTION

Aim
The aim of this study was to describe the clinical and ultrasound features of different subclasses of malignant serous ovarian tumors. According to the new World Health Organization (WHO) classification 1 , serous ovarian carcinomas are categorized as: (1) serous borderline ovarian tumor (BOT); (2) non-invasive low-grade serous carcinoma (LGSC) or serous borderline tumor-micropapillary variant; (3) invasive LGSC; or (4) high-grade serous carcinoma (HGSC).
Background
Epidemiology
Serous BOTs account for 15% of all serous ovarian malignancies, and the incidence of these tumors is considerably lower than that of invasive serous carcinomas 1 . Mean age at diagnosis is 42 years and almost 30% of patients are younger than 40 years 2 .
LGSC is a rare disease, which accounts for less than 10% of all serous ovarian malignancies, and it is usually diagnosed in a younger population than is HGSC 3 . The mean age at diagnosis of patients with a non-invasive LGSC is 45 years, while the mean age of patients with an invasive LGCS is 53 years 1, 3 . HGSCs comprise 75% of all serous ovarian malignancies 4 , and women with a diagnosis of HGSC are older than those with a LGSC, with a mean age of 55-65 years [5] [6] [7] . Ovarian LGSCs and HGSCs have distinct molecular profiles, clinical behavior, and treatment responses. Biological evidence indicates that the two tumor types develop via different pathways 7, 8 . Low-grade serous carcinoma has been hypothesized to arise from a serous cystadenoma or adenofibroma that progresses to borderline tumor to non-invasive LGSC, and then to an invasive counterpart in a slow step-wise fashion. Most patients with these tumors have frequent mutations of the KRAS, BRAF, or ERBB2 gene, and lack TP53 mutations (Type I pathway). In contrast, the development of HGSCs is rapid and their origin has been described as de novo. The vast majority are characterized by TP53 mutations and lack mutations of KRAS, BRAF, or ERBB2 (Type II pathway).
Microscopy
Serous BOTs typically show a hierarchical branching pattern with irregular papillae that branch from large to progressively smaller papillae terminating in detached tufts of epithelial cells. The papillae are lined by non-stratified or stratified columnar cells that are frequently ciliated. The eosinophilic cytoplasm of the cells contains enlarged, hyperchromatic nuclei and sometimes nucleoli 1 . In contrast to the typical borderline tumor, non-invasive
LGSCs show a non-hierarchical pattern, with micropapillary projections five times longer than wide and at least 5 mm in length, with prominent fibrous stalks and a cribriform pattern 9 . The micropapillae have scant or no stromal cores and the cells are cuboidal to polygonal with a high nuclear to cytoplasmic ratio and small, uniform and atypical nuclei. The mitotic index is low but typically higher than that of BOTs. Some typical BOTs can also display foci composed of micropapillae arranged in a non-hierarchical branching architecture, simulating a non-invasive LGSC. However, these BOTs lack the nuclear atypia of non-invasive LGSCs, and the confluent areas of micropapillarity measure less than 5 mm 1 . Invasive LGSCs are frequently associated with a non-invasive component, either serous adenofibroma, borderline or non-invasive LGSC. The invasive component is characterized by micropapillae and small round 'nests' of cells that infiltrate the stroma in a haphazard pattern 8 . The cells show mild to moderate nuclear atypia and may contain a single prominent nucleolus. The mitotic activity is significantly lower than in HGSCs.
HGSCs may exhibit mixtures of papillary, glandular, nested and diffuse/solid growth patterns, although any component may predominate in a given tumor 8 . The papillae tend to be large and complex. Although a micropapillary growth pattern is typical of LGSCs, it should be emphasized that occasional high-grade carcinomas can also exhibit this architecture; however, they have large nuclei and mitoses are numerous and atypical. Obvious destructive stromal invasion is generally present and necrosis is common in this tumor. The neoplastic epithelial cells are heterogeneous and may be a mixture of low-cuboidal, columnar and hobnail shapes.
Macroscopy
Serous BOTs and non-invasive
LGSCs present similar macroscopic features. They are typically cystic, larger than 5 cm and bilateral in one third of cases. Papillary elements are typically present within the cyst, but they may also be present on the outer wall of the cyst ('surface components') 1 . Non-invasive LGSCs are more often bilateral than are BOTS, and the growth of papillary elements on the outer surface of the cyst is more frequently present in non-invasive LGSCs than in serous BOTs 9 . Invasive LGSCs usually exhibit a papillary growth both inside and outside the cyst cavity. Necrosis is rare, whereas calcification is often present and may be extensive. They are frequently bilateral 1, 8 . HGSCs usually exhibit a solid papillary growth outside the cyst cavity and present fluid-filled cysts. The solid part is white and contains extensive necrosis and hemorrhage. The tube can be involved and often is not readily identifiable. They are frequently bilateral and can be variable in size 1 .
Clinical features and prognosis
The vast majority of borderline cases appear to be confined to the ovaries 9 . However, 13% of patients with a serous BOT present with extra-ovarian disease ('implants'), mostly in the omentum or peritoneal surface; 11% have non-invasive implants, whereas around 2% have invasive implants 9, 10 . Women with BOTs without implants have an overall survival comparable with the overall survival expected from the general female population of the same age (overall 5-and 10-year survival rates are 99% and 98%, respectively). However, for women with a BOT with implants, the overall 5-and 10-year survival rates are 95% and 90%, respectively, for those with non-invasive implants and 75% and 60%, respectively, for those with invasive implants 10 . The prognosis of non-invasive LGSCs is not different from that of BOTs. Yet, compared to BOTs, non-invasive
LGSCs present with implants in 26% of cases (13% of patients have non-invasive implants and 13% have invasive implants) 10 . Invasive LGSCs are often asymptomatic and detected only incidentally. The prognosis of tumors confined to the ovary (International Federation of Gynecology and Obstetrics (FIGO) Stage I) is excellent with surgical therapy alone. However, most patients present with Stages II-IV, and the 5-year survival rate in these cases is 56-85% 1, 7, 11 . Patients with low-grade disease exhibit poor response to adjuvant platinum/taxane-based chemotherapy, which is commonly used for serous ovarian carcinomas. Thus, they remain at high risk of recurrence and cancer-related death [11] [12] [13] [14] [15] [16] . HGSCs are generally symptomatic and present at an advanced stage 17 , and only 2% of HGSC cases are diagnosed at FIGO Stage I 18 . In patients with advanced disease, the most important predictor of survival is complete surgical resection of all visible disease 19 . Five-year survival for patients with completely resected Stage-III tumors is 65%, but for incompletely resected Stage-III tumors it is 20% 20 . Patients with high-grade carcinomas exhibit good response rates to adjuvant platinum/taxane-based chemotherapy. Neoadjuvant platinum/taxane-based chemotherapy (chemotherapy performed before radical surgery) has emerged as a reliable therapeutic strategy for patients with extensive tumors, in whom a complete gross resection at primary debulking surgery is unlikely 21 .
METHODS
We retrospectively analyzed the preoperative ultrasound reports of patients with a histological diagnosis of malignant serous ovarian tumor from two ultrasound centers (Policlinico Gemelli, Catholic University of the Sacred Heart, Rome, Italy and European Institute of Oncology, Milan, Italy) between 2006 and 2015. In particular, 64 cases of BOT, 300 HGSC and 27 cases of LGSC with available printed or digital images were selected from the ultrasound center in Rome. As the number of LGSC was very small, another ultrasound center (in Milan) was approached and asked to select all cases of non-invasive and invasive LGSC with available images from the same study period to add to our data. As a result, an additional 15 LGSC (one non-invasive and 14 invasive) were recruited for the analysis. In both institutions, the histological diagnosis was made by a pathologist dedicated to gynecology who was in charge, during the study period, of almost all gynecological reports. Those cases not originally examined by these two pathologists were reviewed by them for this study. Both pathologists used the same histological criteria according to the WHO Classification 1, 22 and to the 'binary grading system' 1, 6, 7 . The non-invasive cases that were selected before 2014 were originally classified according to the 2003 WHO Classification, which considered two different categories of borderline tumors: 'borderline tumors with papillary pattern' and 'borderline tumors with micropapillary pattern'. Conversely, the new (2014) WHO Classification classifies BOTs with a papillary pattern as borderline tumors and BOTs with a micropapillary pattern as non-invasive LGSCs. Therefore, borderline tumors with micropapillary pattern were classified as non-invasive LGSCs in this work. The invasive cases were classified as invasive low-grade and invasive high-grade carcinomas, according to the 'binary grading system'. All the ultrasound examiners had more than 10 years' experience in gynecological ultrasound.
Three hundred and three (74.6%) of the recruited patients had been included in the International Ovarian Tumor Analysis (IOTA) studies (Phase 2 or 3) and so had been investigated using a standardized examination technique and following a strict research protocol, with predefined clinical and ultrasound information being collected prospectively [23] [24] [25] . The remaining 103 (25.4%) patients had undergone ultrasound examination in a standardized manner using the IOTA terminology. For women included in the IOTA protocols, ultrasound information was obtained from ultrasound databases. For women who had been examined outside the IOTA protocols and for women with ultrasound information (on hyperechoic foci) missing from the IOTA database, one author with more than 10 years' experience in gynecological ultrasound (M.C.M.), who was blinded to the histological findings, retrospectively reviewed the ultrasound reports and stored ultrasound images, and described the presence of the hyperechoic foci.
For women who had been examined outside the IOTA studies, all clinical parameters including age, parity, postmenopausal status, symptoms and CA 125 levels were retrieved from patient records. For women who had been examined within the IOTA studies, the parameters including age, postmenopausal status, parity and CA 125 levels were retrieved from the IOTA database, while information regarding symptoms was collected from patient records.
Surgical treatment (conservative vs non-conservative) and FIGO stage were also noted 26, 27 . Conservative surgery comprised preservation of the uterus, Fallopian tube(s) (one or both) and at least one ovary or part of one. In non-conservative surgery, bilateral salpingo-oophorectomy, with or without hysterectomy, was performed.
Transvaginal and transabdominal scans were performed on each patient to ensure a complete examination of the entire abdominal cavity. All ultrasound examinations were carried out using high-end ultrasound equipment, the frequency of the vaginal probes varying between 5.0 and 9.0 MHz and that of the abdominal probes between 3.5 and 5.0 MHz.
In the case of bilateral adnexal masses, the mass with the most complex ultrasound morphology was considered in our analysis. If both masses had similar ultrasound morphology the larger mass was included. The masses were described using the terms and definitions of the IOTA group, including size and characteristics of the lesion 25 . Solid papillary projections were defined as any solid projections into the cystic cavity arising from the cyst wall or from a septum with a height of at least 3 mm. The largest solid component other than a papillary projection was also measured. In some cases, a solid papillary projection was the largest solid component. If this was the case, the papillary projection was recorded and measured both as a papillary projection and as the largest solid component of the mass. The presence of the ovarian crescent sign 28 , ascites and fluid in the pouch of Douglas was reported, and the presence of hyperechoic foci distributed within the mass was also noted. Ovarian masses were also assessed at color Doppler examination according to the following score: no detectable blood flow (color score = 1), minimal blood flow (color score = 2), moderate blood flow (color score = 3) or highly vascular (color score = 4). The specific diagnosis suggested by the original ultrasound examiner in the original ultrasound report was also reported.
All clinical and ultrasound data were entered into a dedicated Excel file, which was used for statistical analysis (Microsoft Office Excel 2007, Redmond, WA, USA).
RESULTS
Four hundred and six patients had a final diagnosis of serous ovarian tumor on histological examination. A BOT was identified in 64 (15.8%) patients, a non-invasive LGSC was found in 11 (2.7%), an invasive LGSC in 31 (7.6%) and an invasive HGSC in 300 (73.9%) patients.
Demographic data of the patients, clinical parameters, surgical procedure and FIGO staging are shown in The vast majority of the borderline (82.3%) and non-invasive low-grade (90.9%) cases were FIGO Stage I, whereas most invasive low-grade (74.2%) and high-grade (74%) cases were FIGO Stage III.
Sonographic characteristics of the serous cases according to histological type are summarized in Table 2 . The median of the maximum diameter of the mass was 59 echogenicity of cyst fluid was reported as anechoic in almost half (46.9%) of BOTs. Papillary projections were present in 52 (81.3%) BOTs and most of them had more than three projections. The median height of the largest papillary projection was 14 (range, 4-45) mm.
Ultrasound images of non-invasive
LGSCs are shown in Figure 3 . Most (63.6%) were multilocular-solid cysts. Papillary projections were present in nine (81.8%) and most of them had more than three projections. Similar to the borderline cases, the median height of the largest papillary projection was 14 (range, 7-39) mm. The echogenicity of cyst fluid was reported as low level in most cases (73%).
Ultrasound images of invasive LGSCs are shown in Figure 4 . These were described as multilocular-solid cysts in 17 (54.8%) cases and as solid masses in 10 (32.3%) Figure 2 Ultrasound images of borderline serous tumors described as multilocular, multilocular-solid and solid masses. Two (3.1%) borderline cases were described as multilocular cyst, size 45-52 mm (a); 19 (29.7%) borderline cases were described as multilocular-solid cysts, size 31-230 mm, of which 17 (89.5%) presented papillary projections (b-e) and two (10.5%) had a solid component without papillary projections (f). Seven of 64 (10.9%) borderline lesions were solid masses, size 24-136 mm (g-i).
patients. Papillary projections were present in 10 (32.3%) invasive low-grade cases.
Ultrasound images of invasive HGSCs are shown in Figure 5 . The vast majority were defined as multilocular-solid (32.7%) or solid (64.0%) masses, with papillary projections in only 21 (7.0%) cases.
The median diameter of the largest solid component was 26 (range, 4-136) mm in the BOTs, 27 (range, 5-67) mm in the non-invasive LGSCs, 50 (range, 8-136) mm in the invasive LGSCs and 63 (range, 9-188) mm in the HGSCs.
Most serous tumors were vascularized at color Doppler examination, but 7.8% of BOTs, 27.3% of non-invasive LGSCs, 3.2% of invasive LGSCs and 2.3% of HGSCs were not vascularized.
Using subjective assessment, the ultrasound examiner correctly diagnosed 40 (62.5%) BOTs, while five (7.8%) borderline cases were classified as benign and 17 (26.6%) as primary ovarian cancer, and in two (3.1%) cases a specific subjective assessment was not given. One of the five borderline cases misdiagnosed as a benign mass was described as a unilocular cyst with ground-glass echogenicity (suggested to be an ovarian endometrioma) and one was described as multilocular cysts with anechoic echogenicity (suggested to be an ovarian cystadenoma). Of the three remaining misdiagnosed BOTs, one was described as a unilocular-solid lesion with mixed echogenicity (suspected to be a dermoid), one as a unilocular-solid mass with a small papillary projection and without vascularization (suspected to be a cystadenoma) and one as a multilocular-solid cyst with a small vascularized papillary projection (suggested to be an ovarian cystadenofibroma). The BOTs suspected of being primary ovarian cancer were described at ultrasound examination as large cysts with multiple papillary projections or as solid masses.
On the basis of the subjective evaluation by the original ultrasound examiner, five (45.5%) non-invasive LGSCs were suspected to be malignant lesions, five (45.5%) to be borderline and one (9.1%) to be a benign lesion. The non-invasive case misdiagnosed as a benign mass was described at ultrasound examination as a unilocular-solid j k Figure 3 Ultrasound, macroscopic and microscopic images of non-invasive low-grade serous tumors. Four (36.4%) non-invasive low-grade tumors were described as unilocular-solid cysts, size 22-110 mm (a-c) and seven (63.6%) were multilocular-solid masses, size 42-201 mm (d-i). Nine (81.8%) cases had papillary projections (a-g,i) and two (18.2%) had a solid component but no papillations (h). Typical macroscopic feature of non-invasive low-grade tumor is cyst with papillary projections within (j). Microscopically, this tumor is characterized by non-hierarchical architecture in which myriad micropapillae emanate directly from large papillary cores (k).
cyst with a small solid component (5 mm) that was not vascularized at color Doppler examination (suggested to be an ovarian cystadenofibroma). Among the invasive LGSCs, 27 (87.1%) were correctly classified at ultrasound examination as invasive lesions and four (12.9%) were classified as borderline tumors. Two of the four invasive LGSC cancers misdiagnosed as borderline lesions were described as unilocular-solid cysts and two as multilocular-solid lesions. All of them presented very small papillary projections. All except three invasive HGSCs were correctly diagnosed as invasive carcinomas. Two of the three HGSCs misdiagnosed as borderline tumors were described as cysts (one unilocular-solid and one multilocular-solid) with multiple papillations, and one case was described as a multilocular-solid mass with low-level echogenicity and a poorly vascularized solid component.
Satisfactory electronic images or videoclips were available for 386 (95.1%) patients. In the remaining 20 (4.9%) cases, the images were only presented in printed form. 
DISCUSSION
This study shows the ultrasound findings of different subclasses of malignant serous ovarian tumors. We found an overlap in ultrasound appearance between BOTs and non-invasive LGSCs, both presenting as cysts with papillary projections. Similarly, there was an overlap in ultrasound characteristics between invasive LGSCs and HGSCs, as both tumor types appeared multilocular-solid with non-papillary solid components or solid masses. However, the HGSCs were more likely to be solid than were invasive
LGSCs which, in turn, were more often multilocular-solid. Moreover, a considerable number of invasive LGSCs presented hyperechoic foci, which were very rare in the other subclasses of malignant serous ovarian tumors.
The strength of our study is the large series of serous ovarian cancers including all different subtypes as classified by Kurman et al. in the new WHO classification of ovarian cancer 1 . Indeed, to the best of our knowledge, there are only histological and clinical data evaluating j k l the behavior of low-grade serous carcinomas 8, 29 but no published studies describing ultrasound findings of these tumors in a standardized manner. In spite of the low incidence of LGSCs, which account for less than 10% of all serous epithelial ovarian cancers, we were able to study a sufficient number of low-grade tumors to allow us to determine the typical ultrasound features of these masses.
However, our study has some limitations, the main one being the retrospective nature of the analysis. Another potential source of bias in the study is that some ultrasound features, such as hyperechoic foci, were retrospectively retrieved from images. Therefore, further studies should be performed in order to prospectively record all ultrasound information to confirm our findings.
The results of the present study agree well with those of case series describing the ultrasound appearance of BOTs, which typically appear as ovarian cysts with papillary projections [30] [31] [32] [33] . Exacoustos et al. 30 in a retrospective study reporting the sonographic findings that distinguish borderline ovarian tumors from both benign and invasive malignant masses, included 18 cases of serous BOTs and 31 invasive serous ovarian tumors. Similarly to our results, they found that many BOTs (44.4%) had papillary projections, whereas invasive serous carcinomas presented as solid masses without papillary projections. In a prospective multicenter study using the IOTA database, Valentin et al. 34 , describing the ultrasound characteristics of different types of malignancies, included 55 ovarian borderline tumors and 144 primary invasive epithelial ovarian cancers (42 FIGO Stage I and 102 FIGO Stages II-IV), without differentiating serous from other histotypes. Similarly to our results, they found a high proportion of BOTs with papillary projections. On the other hand, they observed a higher prevalence of invasive epithelial ovarian cancers with papillations (67% of epithelial ovarian cancers at Stage I and 41% of epithelial ovarian cancers at Stages II-IV) than that in our series (32% of invasive LGSCs and 7% of HGSCs). However, this discrepancy could be related to the fact that in the paper by Valentin et al. the authors described all epithelial tumors without differentiating mucinous, serous, low grade, high-grade etc.
In contrast to the previous studies, which analyzed epithelial ovarian tumors with different histology in the same series, we selected only cases of malignant serous histotype. This allowed us to make some new observations: (1) papillary projections, which are known to be a typical feature of BOTs, were a morphological feature of all non-invasive serous tumors (borderline and low-grade); (2) HGSCs were characterized by non-papillary solid components together with multiple irregular cystic areas (probably related to necrosis), with papillary projections being very rare; (3) characteristic features of invasive low-grade serous carcinomas are hyperechoic foci, which are the ultrasound representation of the calcifications described by pathologists.
Thus, the ultrasound characteristics of serous tumors described in our paper agree well with the histological features reported in the WHO 2014 classification 1 . Most borderline and non-invasive LGSCs appear as cysts with irregular papillae within the internal cystic wall. Invasive low-grade carcinomas are solid or cystic masses exhibiting solid components (with papillary growth) inside and outside the cystic cavity, often with extensive calcifications. Most high-grade serous carcinomas present solid parts with necrosis, while calcifications are rare.
Although other ultrasound characteristics differed among the four subtypes of serous tumors, such as vascularization of the mass and the presence of the crescent sign, none of them seemed to help in discriminating between these tumors. However, two features are worth mentioning. We found a relatively high rate of BOTs (34.4%) and invasive LGSCs (19.4%) showing the ovarian crescent sign. This is in contrast to the result previously reported by Van Holsbeke et al. 35 , who recognized an ovarian crescent sign in both a lower number of BOTs (16%), and in a lower number of invasive masses (6%). However, they included different types of tumors without discriminating serous from other histology. Another unexpected result of our study is the relatively high rate (27%) of non-invasive LGSCs not being vascularized at color Doppler examination. The results could be explained by the small number of cases (11 cases) and the possibility that, in those cases with a large cyst containing very small papillations, the ultrasound examiner could have missed the vascularization.
In conclusion, the present study has shown that non-invasive LGSCs have similar ultrasound features to those of BOTs, so it is difficult to differentiate these subclasses of tumors preoperatively. However, preoperative discrimination between these two pathological categories is not clinically critical, as these entities have the same clinical and surgical management. On the other hand, preoperatively discriminating between the two invasive serous subtypes (low-grade and high-grade) is crucial, as they constitute two different clinical entities. Low-grade carcinoma is characterized by a relative resistance to chemotherapy and has to be managed surgically, whereas HGSC is characterized by a more aggressive behavior and it is more chemosensitive than is LGSC. Thus, the opportunity to preoperatively distinguish an invasive LGSC from a HGSC on ultrasound examination is clinically important and has a role to play in the management of these tumors.
